Zusammenfassung
Hintergrund: Die polymorphen Genorte der entgiftenden Enzyme Glutathion S-Transferase und Cytochrom
P450 sind neben ihrer klassischen Rolle als risikobeeinflussende Genvariationen mit
der Prognose von Tumorerkrankungen in Verbindung gebracht worden. Methode: Wir beschreiben den Einfluss von GST- und CYP-Polymorphismen auf die Prognoseparameter
initialer Tumorausdehnung, initialer Halslymphknotenbefall, histologischer Differenzierungsgrad
und das rezidivfreie Überleben über fünf Jahre. Ergebnisse: GSTT1 0 war mit fortgeschrittenen und lymphogen metastasierten Pharynxkarzinomen
assoziiert. CYP2D6 PM war mit einem malignen Halslymphknotenbefall assoziiert. Eine
Beeinflussung der 5-Jahresheilung durch ein einzelnes Gen konnte nicht nachgewiesen
werden. Schlussfolgerungen: Erstmalig konnten genetisch determinierte Wirtsfaktoren an den Genorten der entgiftenden
Enzyme mit prognostisch wichtigen Faktoren der Kopf-Hals-Tumorerkrankung in Verbindung
gebracht werden.
Abstract
Background: The polymorphic gene loci of the detoxifying enzymes GST and CYP are susceptibility
factors for head and neck cancer. Recently, they have been associated with outcome
in several cancers. Methods: Accordingly, we have examined, in patients with squamous cell carcinoma (SCC) of
the head and neck, associations between GSTM1, GSTT1, GSTM3, GSTP1, CYP2D6, CYP1A1
and CYP2E1 genotypes and outcome parameters, tumor extension, histological grade,
presence of lymph nodes, and recurrence free survival over 5 years. Genotypes were
determined by PCR; logistic regression and a step-wise model were used to investigate
the influence of the individual genes. Results: GSTT1 0 was associated with T3/T4 tumor lesions in the pharynx and oral cavity (p
= 0.029), but not laryngeal SCC cases. GSTT1 0 was also associated with histological
differentiation (G3) in the oral cavity /pharynx, but not laryngeal SCC cases, although
this association only approached significance (p = 0.069). CYP2D6 PM and HET were
associated with lymph node involvement in the laryngeal SCC cases. Conclusions: The data demonstrate site-dependent associations between GSTT1 null and CYP2D6 PM
and tumor extension and lymph node involvement in SCC of the head and neck.
Schlüsselwörter
Glutathion S-Transferase - Cytochrom P450 - Larynxkarzinom - Pharynxkarzinom - Tumorprognose
Key words
Glutathione S-transferase - Cytochrome P450 - Pharyngeal cancer - Laryngeal cancer
- Cancer prognosis
Literatur
1
Blot W J, McLaughlin J K, Winn D M.
Smoking and drinking in relation to oral and pharyngeal cancer.
Cancer Res.
1988;
48
3282-3287
2
Elwood J M, Pearson J CG, Skippen D H, Jackson S M.
Alcohol, smoking, social and occupational factors in the etiology of cancer of the
oral cavity, pharynx and larynx.
Int J Cancer.
1984;
34
603-612
3 Jahnke V.
Bösartige Tumoren des Larynx. In: Naumann HH, Helms J, Herberhold C, Kastenbauer E (Hrsg) Oto-Rhino-Laryngologie
in Klinik und Praxis, Band 3, Hals. Stuttgart, New York; Georg Thieme Verlag 1995:
388-421
4
Maier H, Gewelke U, Dietz A.
Risk factors for cancer of the larynx: results of the Heidelberg case-control study.
Otolaryngol Head Neck Surg.
1992;
107
577-582
5
Bongers V, Braakhuis B JM, Tobi H, Lubsen H, Snow G B.
The relation between cancer incidence among relatives and the occurrence of multiple
primary carcinomas following head and neck cancer.
Cancer Epidemiol Biomarkers Prev.
1996;
5
585-598
6
Copper M P, Jovanovic A, Nauta J JP, Braakhuis B JM, DeVries N, van der Waal L P,
Snow G B.
Role of genetic factors in the etiology of squamous cell carcinoma of the head and
neck.
Arch Otolarynogol.
1995;
121
157-160
7
Gonzalez M V, Alvarez V, Pello M F, Menendez M J, Suarez C, Coto E.
Genetic polymorphism of N-acetyltransferase-2, glutathione S-transferase M1, and cytochromes
P450 2E1 and P450 2D6 in the susceptibility to head and neck cancer.
J Clin Pathol.
1998;
51
294-298
8
Jahnke V, Strange R C, Matthias C, Fryer A A.
Erste Ergebnisse über Glutathion-S-Transferase GSTM1 und GSTT1 Genotypen und die genetische
Prädisposition beim Larynxkarzinom.
Laryngol Rhinol Otol.
1995;
74
691-694
9
Trizna Z, Clayman G L, Spitz M R, Goepfert H.
Glutathione S-transferase genotypes as risk factors for head and neck cancer.
Am J Surg.
1995;
170
499-501
10
Matthias C, Bockmühl U, Jahnke V, Lorries L W, Wolf C R, Jones P W, Alldersea J, Worrall S F,
Hand P, Fryer A A, Strange R C.
The glutathione S-transferase GSTP1 polymorphism: effects on susceptibility to oral/pharyngeal
and laryngeal carcinomas.
Pharmacogenetics.
1998;
8
1-6
11
Matthias C, Bockmühl U, Jahnke V, Jones P W, Hayes J, Alldersea J, Gilford J, Bailey L,
Bath J, Worrall S F, Hand P, Fryer A A, Strange R C.
Polymorphism in cytochrome P450 CYP2D6, CYP1A1, CYP2E1 and glutathione-S-transferase,
GSTM1, GSTM3, GSTT1 and susceptibility to tobacco-related cancers: studies in upper
aerodigestive tract cancers.
Pharmacogenetics.
1998;
8
91-100
12
Oude-Ophuis M B, van Lieshout E M, Roelofs H M, Peters W H, Manni J J.
Glutathione S-transferase M1 and T1 and cytochrome P450 1A1 polymorphisms in relation
to the risk for benign and malignant head and neck lesions.
Cancer.
1998;
82
936-43
13
Park J Y, Muscat J E, Ren Q, Schantz S P, Harwick R D, Stern J C, Pike V, Richie J P,
Lazarus P.
CYP1A1 and GSTM1 polymorphisms and oral cancer risk.
Cancer Epidemiol Biomarkers Prev.
1997;
6
791-797
14
Janot F, Klijanienko J, Russo A, Mamet J P, de Braud F, El-Naggar A K, Pignon J P,
Luboinski B, Cvitkovic E.
Prognostic value of clinicopathological parameters in head and neck squamous cell
carcinoma: a prospective analysis.
Br J Cancer.
1996;
73
531-538
15
Magnano M, Bussi M, de Stefani A, Milan F, Lerda W, Ferrero V, Gervasio F, Ragona R,
Gabriele P, Valente G, Cortesina G.
Prognostic factors for head and neck tumor recurrence.
Acta Otolaryngol (Stockh).
1995;
115
833-838
16
Issing W J, Wustrow T PU, Heppt W.
Onkogene und ihre Bedeutung für Kopf- und Halskarzinome.
HNO.
1992;
40
283-291
17
Müller D, Millon R, Lidereau R, Engelmann A, Bronner G, Flesh H, Eber M, Methlin G,
Abecassis J.
Frequent amplification of 11q13 DNA markers is associated with lymph node involvement
in human head and neck squamous cell carcinomas.
Eur J Cancer.
1994;
30
113-120
18
Watling D L, Gown A M.
Overexpression p53 in head and neck cancer.
Head Neck.
1992;
14
437-444
19
Bockmühl U, Petersen S, Schmidt S, Petersen I, Dietel M.
Patterns of chromosomal alterations in metastasizing and non-metastasizing primary
head and neck carcinomas.
Cancer Res.
1997;
57
5213-5216
20
Field J K, Kiaris H, Risk J M, Tsiriyotis C, Adamson R, Zoumpourlis V, Rowley H, Taylor K,
Whittaker J, Howard P, Beirne J C, Gosney J R, Woolgar J, Vaughan E D, Spandidos D A,
Jones A S.
Allelotype of squamous cell carcinoma of the head and neck: fractional allele loss
correlates with survival.
Br J Cancer.
1995;
72
1180-1188
21
Kawajiri K, Eguchi H, Nakachi K, Sekija T, Yamamoto M.
Association of CYP1A1 germ line polymorphisms with mutations of the p53 gene in lung
cancer.
Cancer Res.
1996;
56
72-76
22
Lazarus P, Sheikh S N, Ren Q, Schantz S P, Stern J C, Richie J P, Park J Y.
p53, but not p16 mutations in oral squamous cell carcinomas are associated with specific
CYP1A1 and GSTM1 polymorphic genotypes and patient tobacco use.
Carcinogenesis.
1998;
19
509-514
23
Perera F P.
Molecular epidemiology: insights into cancer susceptibility, risk assessment and prevention.
J Natl Cancer Inst.
1996;
88
496-509
24
Chouaib S C, Asselin-Paturel F, Mami-Chouaib F, Caignard A, Blay J Y.
The host-immune conflict: from immunosuppression to resistance and destruction.
Immunol Today.
1997;
18
493-497
25
Brockmöller J, Cascorbi I, Kerb R, Roots I.
Combined analysis of inherited polymorphisms in arylamine N-acetyltransferase 2, glutathione
S-transferase M1 an T1, microsomal epoxide hydrolase, and cytochrome P450 enzymes
as modulators of bladder cancer risk.
Cancer Res.
1996;
56
3915-3925
26
Worrall S F, Corrigan M, High A, Starr D, Matthias C, Wolf R C, Jones P W, Hand P,
Gilford J, Farrell W E, Hoban P, Fryer A A, Strange R C.
Susceptibility and outcome in oral cancer: preliminary data showing an association
with polymorphism in cytochrome P450 CYP2D6.
Pharmacogenetics.
1998;
8
433-439
27
Ingelman-Sundberg M, Johansson I, Persson I, Yue Q Y, Dahl M L, Bertilsson L, Sjoqvist F.
Genetic polymorphism of cytochrome P450: interethnic differences and relationship
to incidence of lung cancer.
Pharmacogenetics.
1992;
2
264-271
28
Goto I, Yoneda S, Yamamoto M, Kawajiri K.
Prognostic significance of germ line polymorphisms of the CYP1A1 and glutathione S-transferase
genes in patients with non-small cell lung cancer.
Cancer Res.
1996;
56
3725-3730
29
Harries L W, Stubbins M J, Forman D, Howard G CW, Wolf C R.
Identification of genetic polymorphism at the GSTP1 locus and association with susceptibility
to bladder, testicular and prostate cancer.
Carcinogenesis.
1997;
18
1221-1226
30
Matthias C, Branigan K, Jahnke V, Leder K, Haas J, Heighway J, Jones P W, Strange R C,
Fryer A A, Hoban P R.
Polymorphism within the cyclin D1 gene is associated with prognosis in patients with
squamous cell carcinoma of the head and neck.
Clin Cancer Res.
1998;
4
2411-2418
Priv.-Doz. Dr. C. Matthias
HNO-Klinik der Charité, Campus Virchow-Klinikum der Humboldt-Universität
Augustenburger Platz 1 · 13353 Berlin
eMail: christoph.matthias@charite.de